Category Archives: Medical

Plague vaccine patent by iBio clears opposition period


Bio-tech company iBio Inc. received a notice from the European Patent Office that said the opposition period has passed on an iBio plague vaccine patent, the company said on Monday. The vaccine uses antigens against Yersinia pestis to prevent the … Read More »

AIRES system enters clinical trials


Luminex Corp.’s ARIES System and HSV 1&2 Assay have entered the clinical trial phase, the company announced on Monday. The system aims to streamline laboratory procedure and to enhance testing efficiency with internal scanning that minimizes error from operators.¬†Each unit … Read More »

NIH Ebola patient’s condition improves


A patient at the National Institutes of Health (NIH) research hospital who is being treated for Ebola virus disease (EVD) is improving, with a condition that is considered fair as opposed to serious, the NIH announced on Monday. The patient … Read More »

FDA approves anthrax treatment Anthrasil


The Food and Drug Administration approved the anthrax treatment Anthrasil from Emergent BioSolutions, the company said on Wednesday. The treatment is an Anthrax Immune Globulin Intravenous (AIGIV) solution that consists of polyclonal antibodies that target the damaging portions and toxic … Read More »

Ebola diagnostic receives emergency use authorization


The Food and Drug Administration has allowed the Xpert Ebola test from Cepheid to be used through an emergency use authorization, the company announced on Tuesday. The test is specified for the Zaire strain of Ebola virus disease (EVD) and … Read More »

Tru-D, HealthTrust reach agreement


HealthTrust has reached an agreement with Tru-D Smart UVC, LLC, to provide its network of health care facilities with disinfection robots, the latter announced Wednesday. The network consists of 1,359 facilities in over 15,000 locations nationwide that include surgery centers, … Read More »

Emergent BioSolutions signs BARDA contract for NuThrax development


Emergent BioSolutions, Inc., announced the signing of a contract on Tuesday with the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of NuThrax. NuThrax, anthrax vaccine adsorbed with CPG 7909 adjuvant, also known as AV7909, is Emergent’ … Read More »

Routine immunization needed in Ebola-affected countries


The World Health Organization (WHO) on Friday appealed for the enhancement of immunization distribution in countries that have been affected by the Ebola virus in order to prevent diseases that have vaccines, such as measles and malaria. Due to the … Read More »

Researchers study improved delivery methods for antibiotics in respiratory infections


Researchers from Brazil, Germany and France recently have found that delivery of antibiotics via nanoparticles increases efficacy in cases of respiratory infection. They detailed their findings at the European Respiratory Society conference on Friday. The test was based on Staphylococcus … Read More »

Emergent BioSolutions signs agreements for production of MVA Ebola Zaire vaccine candidate


Emergent BioSolutions, Inc., announced agreements on Monday for a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) that it anticipates for use in a Phase 1 clinical study that will be conducted by Professor Adrian Hill of the … Read More »

Tekmira to begin Phase II trials on Ebola-Guinea drug


Tekmira Pharmaceuticals, a therapeutic-solutions company that has been developing a cure for hepatitis B virus, said on Wednesday that its TKM-Ebola-Guinea drug therapy will be evaluated for possible use on Ebola patients in Sierra Leone, West Africa. The drug, which … Read More »

Soligenix releases new data from RiVax pre-clinical trials


Soligenix released additional data on Wednesday from pre-clinical trials of its vaccine candidate against ricin toxicity, RiVax. In nonhuman primate trials, the vaccine was shown to be effective and provided protection against ricin poisoning at a 100 percent rate. Animals … Read More »

Pfenex extends contract with Glide Technologies


Glide Technologies¬†will continue to develop an alternate delivery method of a recombinant protective antigen developed by PFEnex as part of a subcontract extension with the company that was recently announced. Pfenex’s compound is a vaccine candidate against the anthrax infection … Read More »

Clinical managing methods for bioterrorism-related infections


The New England Journal of Medicine recently released a review discussing how health professionals clinically manage infections and pathogens that can be used as bioweapons. The review is based on historical incidents and information about the simplicity of contagiousness, dissemination, … Read More »

Merck to enter Ebola Vaccine Investigational agreement


Merck Vaccines and NewLink Genetics Corporation will enter a cooperative agreement to research, manufacture and develop an investigational vaccine candidate for the Ebola virus. The vaccine candidate was originally developed by the Canadian Public Health Agency and is in the … Read More »